PUVA and cancer: a case-control study.
A detailed case-control study was carried out on 24 PUVA-treated patients with squamous cell cancer of the skin, and on an accurately matched control population of 96 PUVA-treated patients. Possible co-carcinogens, such as prior therapy with tar, ultraviolet-B, ionizing radiation, methotrexate and arsenic, were investigated. The only statistically significant association to emerge was that of prior therapy with methotrexate: relative risk 3.5; 95% confidence interval 1.2-9.9. Our data suggest that prior therapy with methotrexate might be a risk factor for skin cancer in PUVA-treated patients.
Lindelöf
B
B
Department of Dermatology, Karolinska Hospital, Stockholm, Sweden.
Sigurgeirsson
B
B
D000328:Adult; D000368:Aged; D001151:Arsenic / Q000009:adverse effects; D002294:Carcinoma, Squamous Cell / Q000209:etiology*; D016022:Case-Control Studies; D003033:Coal Tar / Q000009:adverse effects; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D006918:Hydroxyurea / Q000009:adverse effects; D008297:Male; D008727:Methotrexate / Q000009:adverse effects*; D008875:Middle Aged; D011701:PUVA Therapy / Q000009:adverse effects*; D011878:Radiotherapy / Q000009:adverse effects; D012878:Skin Neoplasms / Q000209:etiology*; D014467:Ultraviolet Therapy / Q000009:adverse effects; D014965:X-Rays / Q000009:adverse effects
D003033:Coal Tar; D001151:Arsenic; D006918:Hydroxyurea; D008727:Methotrexate